Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 210Breast Neoplasms 116Neoplasms 111Colorectal Neoplasms 94Multiple Myeloma 87Prostatic Neoplasms 83Neoplasm Metastasis 71Ovarian Neoplasms 69Lung Neoplasms 67Recurrence 57Squamous Cell Carcinoma of Head and Neck 55Pancreatic Neoplasms 47Stomach Neoplasms 42Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Large B-Cell, Diffuse 39Small Cell Lung Carcinoma 38Melanoma 37Lymphoma, Non-Hodgkin 37Leukemia, Myeloid, Acute 37Parkinson Disease 4, Autosomal Dominant Lewy Body 36Carcinoma, Renal Cell 36Advanced Solid Tumors 35Endometrial Neoplasms 34Triple Negative Breast Neoplasms 29Lymphoma, Follicular 29Urinary Bladder Neoplasms 26Head and Neck Neoplasms 26Carcinoma, Hepatocellular 25Myasthenia Gravis 23Esophageal Neoplasms 23

Interventions

darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × High-Risk Localized Prostate Cancer × 30 days × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡